Breaking News:
FDA approval for Guselkumab
First MorphoSys-antibody approved
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic programs and project advancements in our Annual Report 2016.
Engineering the medicines
of tomorrow
Learn how MorphoSys approaches drug development.
Hematological cancers
affect adults and children alike.
MorphoSys is developing several blood cancer programs.
Antibody drugs have transformed the way
inflammatory and autoimmune diseases are treated today.
MorphoSys is exploring new approaches to continue this success.
Solid tumors can occur in
several organs of the human body.
MorphoSys and its partners are working on a broad portfolio of new therapies.
MorphoSys's vision
21/07/2017
MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of...
14/07/2017
MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval...
05/06/2017
MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination...
05/06/2017
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in...
02/06/2017
MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients...
24/05/2017
MorphoSys Announces That Its Licensee Janssen Reported Updates on the...
19/05/2017
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide...
18/05/2017
MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming...
